Beckman Coulter Life Sciences and IncellDx, Inc. announced today they have signed a distribution agreement which focuses exclusively on clinical researchers in China, Hong Kong and Taiwan working on the Human Papilloma Virus (HPV) and cancer. 

The commercial partnership brings the power of multi-parameter flow cytometry to molecular testing, improving workflow while delivering sensitive and highly reliable cell identification.

IncellDx’s next generation (3Dx) investigational molecular assay used to quantify HPV E6, E7 mRNA in single cells has been specially optimized to run on Beckman Coulter’s innovative CytoFLEX flow cytometry system.* The high throughput system instrument has the precision to integrate E6, E7 mRNA overexpression with the measurement of cell cycle and cell proliferation.

"The CytoFLEX easily fits into today’s rapid workflow in research cytometry – combining ease of use with exceptional analytical performance and built-in automation,” said Mario Koksch, Vice President and General Manager of the Beckman Coulter Flow Cytometry Business Unit.

“This innovative partnership with IncellDx enables us to expand our product offerings in clinical research applications, further strengthening the company’s growing infectious diseases portfolio.”

Bruce Patterson MD, CEO of IncellDx commented: “We are excited about this opportunity to bring molecular testing to the flow cytometry field in a region of the world with a great appetite for innovation in the molecular space. The hallmark of cancer research is the quantification of oncogenes E6 and E7 in cells from the cervix, anus, or head and neck. However, as cytology samples contain a heterogeneous mixture of normal and abnormal cells, it is critical that we are able to carry out quantification at the single cell level.”

About IncellDx

IncellDx is a molecular diagnostics company dedicated to revolutionizing healthcare one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, the company’s focus is on critical life threatening diseases in the areas of cancer, specifically cervical, head and neck, breast, thyroid and prostate cancers. 

About Beckman Coulter Life Sciences

Beckman Coulter Life Sciences, a division of Beckman Coulter, Inc., is dedicated to improving the health of people around the world. The company's global leadership and world-class service and support delivers sophisticated instrument systems, reagents and services to life science researchers in academic and commercial laboratories, enabling new discoveries in biology-based research and development.

more about beckman coulter

more news from beckman coulter